Stocktoria
Avalo Therapeutics, Inc. AVTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-11-13
Avalo Therapeutics, Inc. statistics & valuation
Market cap$956.7M
P / B11.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -123601.7% | -15535.6% | -1421.6% | -207.4% | -1521.6% |
| Net margin | -132642.4% | -7965.8% | -1639.5% | -230.8% | -1563.1% |
| FCF margin | — | — | — | -148.7% | -1315.4% |
| Return on assets | -67.2% | -23.3% | -150.3% | -124.8% | -105.2% |
| Return on equity | -94.2% | -26.4% | -431.9% | 381.7% | -365.5% |
| Current ratio | 8.14 | 19.96 | 1.82 | 0.74 | 3.11 |
| Revenue growth | -86.6% | -77.1% | -89.3% | 234.4% | -19.4% |
Source: SEC EDGAR filings · CIK 0001534120 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.